Drugs / Tirellizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07267286 | Dec 2024 → Aug 2028 expected | head and neck squamous cell carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tirellizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07267286 ↗ |
| Action | Inhibit | “As a uniquely modified PD-1 inhibitor” NCT07267286 ↗ |
| Modality | Monoclonal antibody | “Tirellizumab is a humanized IgG4 monoclonal antibody against PD-1” NCT07267286 ↗ |
| Route | Intravenous | “Tirelizumab will be administered by intravenous infusion” NCT07267286 ↗ |